Table 3.

Treatment-related adverse events in the two groups.

		TACE+AC (n = 34)				TACE+A (n = 68)				P value
Adverse events
	Toxicity grade	1/2		3/4		1/2		3/4
TACE-related
	Diarrhea	6	17.6%	1	2.9%	14	20.6%	5	7.4%	0.268
	Transaminitis	13	38.2%	3	8.8%	26	38.2%	5	7.4%	1
	Rash	4	63.7%	0	0.0%	11	16.1%	3	4.4%	0.409
	Nausea with/without vomiting	22	64.7%	2	5.9%	31	45.6%	5	7.4%	0.135
	Abdominal pain	19	55.9%	4	11.7%	42	61.7%	9	13.2%	0.641
	Fatigue	7	29.0%	0	0.0%	4	5.8%	3	4.4%	0.221
	Fever	19	26.5%	3	8.8%	33	48.5%	0	0.0%	0.144
	Leukopenia	6	17.6%	1	2.9%	8	11.7%	0		0.249
	Neutropenia	5	14.7%	1	2.9%	6	8.8%	0		0.208
	Lymphopenia	4	11.8%	1	2.9%	5	7.4%	1	1.5%	0.499
	Thrombopenia	7	20.6%	0	0.0%	12	17.6%	0	0.0%	0.789
	Anemia	6	17.6%	0	0.0%	8	11.7%	0	0.0%	0.543
	Decreased appetite	6	17.6%	0	0.0%	24	35.2%	0	0.0%	0.071
Apatinib and Camrelizumab -related	Hand-foot skin reactions	7	11.7%	3	8.8%	20	29.4%	8	11.7%	0.283
	Hypertension	11	32.4%	4	11.7%	16	23.5%	11	16.1%	0.676
	REECP	7	29.0%	1	2.9%	0		0		–
	all	34	100.0%	11	32.3%	64	100.0%	16	23.5%	0.298